Last edition
News about Market
Marksans Pharma's UK Arm Relonchem Receives UK MHRA Approval for Mefenamic Acid Tablets
Marksans Pharma announced that its wholly owned UK subsidiary, Relonchem, has received marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for mefenamic acid 250 mg and 500 mg film-coated tablets. The approval further expands Relonchem’s growing footprint in the UK generics market.
Market | 17/11/2025 | By Dineshwori
DOMINA and SOLIDA: New Generation of Tablet Presses from IMA Active
Let's take a look at a new generation of tablet presses from IMA Active, DOMINA and SOLIDA, which are poised to change the meaning of production in the pharmaceutical industry.
Market | 15/11/2025 | By Dineshwori
SCRI and Bristol Myers Squibb have expanded their collaboration to accelerate patient enrollment and extend access to advanced cancer clinical trials. By leveraging a data-driven strategy, the partnership aims to bring innovative research opportunities to a broader range of communities.
Market | 15/11/2025 | By Dineshwori
German-based pharmaceutical machinery manufacturer Romaco is expanding its footprint in India with the localisation of format part production for its Noack 900 blister packaging machine series.
Market | 15/11/2025 | By Dineshwori
Zydus Receives Final Approval from USFDA for Leuprolide Acetate Injection
Zydus has secured final USFDA approval for its Leuprolide Acetate injection, a multiple-dose formulation indicated for the palliative treatment of advanced prostate cancer.
Market | 15/11/2025 | By Dineshwori
Under the terms of the partnership, Transition Bio is responsible for the discovery and optimisation of small molecules targeting TDP-43 until nomination of a development candidate, upon which Voyager will have an option to license the worldwide exclusive rights to develop and commercialise the programme.
Market | 15/11/2025 | By Dineshwori
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Market | 15/11/2025 | By Dineshwori
Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment
After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.
Market | 14/11/2025 | By Darshana
Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion
Merck & Co. is reportedly closing in on the acquisition of Cidara Therapeutics, a biotechnology company focused on long-acting antibody treatments for influenza. The deal is expected to value Cidara above its USD 3.3 billion market capitalisation.
Market | 14/11/2025 | By Darshana
Natural Capsules Posts Stable Q2, but US Tariffs Slow HPMC Expansion
Natural Capsules, one of India’s leading capsule manufacturers, has announced its financial results for the quarter and half year ended September 30, 2025, reporting steady demand but acknowledging multiple external and operational challenges that have impacted growth.
Market | 14/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy